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Abstract
Background: Procalcitonin (PCT) is closely correlated with parasite burden and clinical outcome
in falciparum malaria. The role of PCT in tertian malaria has not previously been investigated.
Patients and methods: PCT serum levels in 37 patients with tertian malaria were analysed.
Clinical and laboratory parameters were assessed and statistically correlated both to the initial PCT
levels and during the course of the disease.
Results:  PCT levels rose for one day after commencing treatment and declined thereafter.
However, there was no significant correlation with parasite burden, clinical parameters, laboratory
values, or the presence of semi-immunity. Before treatment, the majority of patients showed
normal or slightly elevated PCT levels (< 2.5 ng/ml), but PCT was markedly elevated (4.8 – 47 ng/
ml) in one third of the population. The two groups did not differ by any other of the assessed
parameters. Thus, while the post-treatment course of PCT resembles falciparum malaria, the lack
of correlation between disease severity and even high PCT levels in a large proportion of patients
is intriguing.
Conclusions: There is a fundamental difference in the relationship of PCT with tertian malaria not
seen in other infectious diseases in which elevated PCT levels have been observed. This suggests
distinct pathophysiological pathways in malaria.
Background
Procalcitonin (PCT) is elevated in serum of patients with
severe infections of bacterial or parasitic origin [1].
Increased levels have also been described in falciparum
malaria [2–6]. It has been recently demonstrated that PCT
levels in falciparum malaria correlate with parasitemia
and disease severity, and that markedly elevated values (>
25 ng/ml) are associated with a high risk of fatal outcome
[5]. In this study, PCT levels were investigated in patients
with tertian malaria, which is generally mild without
severe organ complications and which is usually non-
fatal.
Patients and methods
Patients with malaria who are seen at the site of the study
follow a standard protocol for prospective assessment of
relevant parameters. Thirty seven unselected, consecutive
patients with tertian malaria due to Plasmodium vivax or
Plasmodium ovale seen during 2000 and 2001 and in
whom all necessary data were available, were analysed.
Concomitant infections with a possible impact on PCT
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levels were excluded by history, clinical examination, and
laboratory tests. Patients who were raised in an area
endemic for tertian malaria were defined as semi-immune
(n = 12). Blood samples were drawn immediately before
treatment (day 0) and on follow-up until day 7. Some of
the samples were stored at -80°C until analysis. PCT
serum levels were determined using an immuno-lumino-
metric assay (LUMItest PCT, BRAHMS Diagnostica
GmbH, Berlin, Germany) according to the manufacturer's
specifications. Routine laboratory investigations included
differential blood count, haemoglobin, platelets, standard
coagulation tests, creatinine, neopterin, C-reactive pro-
tein, lactate dehydrogenase and liver function tests.
Patients were monitored by physical examination, ECG,
abdominal ultrasound, and chest radiography. All but two
patients received chloroquine for treatment. Two patients,
in whom the plasmodium species could not be differenti-
ated by the first blood sample, received mefloquine.
Results were compared with data obtained at the same site
in a cohort of Plasmodium falciparum patients and pub-
lished earlier [5].
Results
The median reported duration of illness before diagnosis
was 3.5 days. All patients had a low or modest parasitemia
(< 1%), haemoglobin concentrations >12 g/dl (except
two patients with 8.4 and 10.7 g/dl), normal renal and
liver function, and no signs of concomitant infections.
The disease progression was always mild with a rapid par-
asite clearance in response to anti-malarial treatment.
None of the patients had fever after day three. Initial PCT
concentrations varied between < 0.1 ng/ml and 47 ng/ml
and, in all patients, dropped with declining parasite
counts and clinical recovery (Figure 1). Only few patients
had slightly elevated PCT levels after complete parasite
clearance. PCT levels before treatment did not correlate
with parasite burden, laboratory values, reported duration
of illness, body temperature or fever attacks, or the pres-
ence of semi-immunity. Before treatment, two thirds of
the patients showed normal (< 0.5 ng/ml) or slightly ele-
vated PCT levels (geometric mean 0.44 ng/ml, range < 0.1
– 2.1). In a subset of patients (12/37), however, PCT was
markedly elevated (geometric mean 14.4 ng/ml; range 4.8
– 47). PCT in these patients was in the range of patients
with severe and complicated falciparum malaria (> 2.5
ng/ml, Figure 2). The two groups with low or high PCT
were undistinguishable by means of history, clinical signs,
or laboratory parameters. In particular, secondary infec-
tions or other possibly explanatory conditions could not
be identified.
Discussion
In contrast to falciparum malaria and other infectious dis-
eases in which PCT is induced, markedly elevated PCT lev-
els could be observed in this cohort in one third of the
Serum procalcitonin (PCT) concentrations in 37 patients  with tertian malaria immediately before treatment (day 0),  and on follow-up Figure 1
Serum procalcitonin (PCT) concentrations in 37 patients 
with tertian malaria immediately before treatment (day 0), 
and on follow-up. Box: median, 25th, and 75th percentile; 
whiskers: 5th and 95th percentile; star: 1st and 99th percentile; 
open squares: mean; filled circles: geometric mean.
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PCT levels before treatment in patients with tertian malaria  (triangles) compared to falciparum malaria (open squares:  survivors; filled squares: patients that died) Figure 2
PCT levels before treatment in patients with tertian malaria 
(triangles) compared to falciparum malaria (open squares: 
survivors; filled squares: patients that died). Cluster A: semi-
immune patients; cluster B: non-immune patients with mild 
disease; cluster C: non-immune patients with severe and 
complicated disease. The horizontal line at 2.5 ng/ml is the 
lower cut-off for complicated falciparum malaria and arbitrar-
ily discriminates a high level from a low level group in tertian 
malaria. Falciparum malaria data originate from another 
study).)[5].
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patients without any correlation to disease severity. This
could not be attributed to concomitant infections or com-
plications. While the study was not statistically powered
to significantly detect weak correlations, the large number
of patients with high PCT levels is intriguing. Although
the pathophysiology of PCT has not been determined yet,
the question remains, what is so different in tertian
malaria. In contrast to bacterial or other infectious dis-
eases, tertian malaria is characterized by surges in parasitic
density and fever every 48 hours, leaving time in-between
for the defence system to recover. The magnitude of PCT
induction may also depend on host factors. It would be
interesting to find out whether such host factors indicated
an individual risk of developing severe falciparum
malaria.
Conclusions
The unique feature of PCT induction in tertian malaria
raises interesting questions about the clinical and patho-
physiological role of PCT in infectious diseases and in
malaria in particular. This should stimulate further
research on PCT and malaria pathophysiology.
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